// App-Quantinova.ai

PB2339 : PROJECTED LIFETIME ECONOMIC BURDEN OF TRANSFUSION DEPENDENT BETA-THALASSEMIA IN THE UNITED STATES

Researchers

Presenter

  • Chuka Udeze

Principal Investigators

  • Andrea Lopez

Medical Centers

  • Servier Pharmaceuticals LLC,Boston,Estados Unidos

  • Servier Pharmaceuticals LLC,Boston,Verenigde Staten

  • Vertex Pharmaceuticals Incorporated, Boston, United States of America

  • HCD Economics,The Innovation Centre,Daresbury,Royaume-uni

  • HCD Economics,The Innovation Centre,Daresbury,Royaume-uni

  • HCD Economics,The Innovation Centre,Daresbury,Vereinigtes Königreich

  • Servier Pharmaceuticals LLC,Boston,Verenigde Staten

  • X4 Pharmaceuticals,Boston,Stati Uniti

  • X4 Pharmaceuticals,Boston,USA

  • HCD Economics,The Innovation Centre,Daresbury,Royaume-uni

  • Servier Pharmaceuticals,Boston,États-unis

  • HCD Economics,The Innovation Centre,Daresbury,Storbritannien

  • HCD Economics,The Innovation Centre,Daresbury,Royaume-uni

  • HCD Economics,The Innovation Centre,Daresbury,Соединённое Королевство

  • HCD Economics,The Innovation Centre,Daresbury,Vereinigtes Königreich

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Ophthalmology (OP)

  • Endocrine/metabolic Diseases (ME)

Disease

  • Beta-thalassemia

  • Diabetes

Biomarkers

  • Tumor doubling time

Drug/Treatment

  • luspatercept

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved